EVANT:

Active substances:

Eimeria acervulina, strain 003 .................... 332 – 450*

Eimeria maxima, strain 013 ........................ 196 – 265*

Eimeria mitis, strain 006 ............................. 293 – 397*

Eimeria praecox, strain 007 ........................ 293 – 397*

Eimeria tenella, strain 004 .......................... 276 – 374*

* Number of sporulated oocysts derived from precocious attenuated lines of coccidia,

according to in vitro procedures of the manufacturer at the time of blending.

Adjuvant and excipients:

HIPRAMUNE T:

HIPRACELL:

INDICATION(S):
For the active immunisation of chicks from 1 day of age to reduce intestinal lesions and oocysts output associated with coccidiosis caused by Eimeria acervulina, Eimeria maxima, Eimeria mitis, Eimeria praecox and Eimeria tenella and to reduce clinical signs (diarrhoea) associated with Eimeria acervulina, Eimeria maxima and Eimeria tenella.

Onset of immunity: 14 days post-vaccination.

Duration of immunity: 63 days post-vaccination in an environment that permits oocysts recycling.

TARGET SPECIES:
Chickens.

DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION:
One dose of vaccine (0.007 ml) from 1 day of age. Oral use. The method of administration is by coarse spray.

ADVICE ON CORRECT ADMINISTRATION:
The method of administration is by coarse spray by using a suitable device (volume delivered: 28 ml/100 chicks, droplet size: 200 – 250 μm and working pressure: 1.5 to 3 bars). Before starting to prepare the spray solution, ensure there is a clean container with suffIcient capacity for preparing the diluted vaccine suspension available. Dilute the vaccine with the relevant volumes of the solvent (HIPRAMUNE T or HIPRACELL) and water, as shown in the following table:

DOSES	WATER	VACCINE	SOLVENT	TOTAL
1,000	223 ml	7 ml	50 ml	280 ml
5,000	1,115 ml	35 ml	250 ml	1,400 ml
10,000	2,230 ml	70 ml	500 ml	2,800 ml

Shake the solvent vial (HIPRAMUNE T or HIPRACELL). Dilute the contents of the vial with clean, room temperature water into an appropriate container. Shake the vaccine (EVANT) vial and dilute the contents of it into the solvent and water solution. A purplish suspension is obtained after dilution. Fill the reservoir of the spraying device with all the vaccine suspension prepared. Maintain the diluted vaccine suspension in continuous homogenisation by using a magnetic stirrer while the vaccine is being administered via coarse spray to the chicks.

To improve the uniformity of the vaccination, maintain the chicks inside the transportation box for at least 1 hour in order to let them ingest all the vaccine droplets. After this time, place the chicks carefully into the litter and continue with regular management practices. The device should be cleaned after each use. See the manufacturer’s instructions to ensure proper disinfection and maintenance of the device.

CONTRAINDICATIONS:
None.

ADVERSE REACTIONS:
None.
If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon.

SPECIAL STORAGE PRECAUTIONS:
Keep out of the sight and reach of children.
Store and transport refrigerated (2 ºC - 8 ºC). Do not freeze.
Shelf life after dilution according to directions: 10 hours.
Do not use this veterinary medicinal product after the expiry date which is stated on the carton and the label.

Special warnings for each target species
The vaccine will not protect species other than chickens against coccidiosis and is only effective against the Eimeria species indicated. This product is intended for the vaccination of short-lived chickens only. No data is available on protection of longer-lived birds such as future layers/breeders.

Special precautions for use in animals
Vaccinate healthy chickens only.
Chickens must be strictly foor-reared in the first 3 weeks after vaccination.
In order to reduce field infections, it is recommended that all litter should be removed and facilities and related equipment in contact with vaccinated chickens should be cleaned between production cycles.

The safety of the veterinary medicinal product has not been established during lay. Do not use in birds in lay or in breeding birds, or within 4 weeks before the start of the laying period.

Special precautions to be taken by the person administering the veterinary medicinal product to animals
Wash and disinfect hands and equipment after use.

Interaction with other medicinal products and other forms of interaction
No information is available on the safety and efficacy of this immunological veterinary medicinal product when used with any other veterinary medicinal
product. A decision to use this immunological veterinary medicinal product before or after any other veterinary medicinal product therefore needs to be
made on a case by case basis.
No anticoccidial substances or other agents having anticoccidial activity via feed or water should be used for at least 3 weeks following the vaccination of chickens with this product otherwise the correct replication of the vaccine oocysts, and consequently the development of a solid immunity, could be
hindered. Additionally, the duration of immunity depends on an environment that permits recycling of oocysts, therefore a decision to use any anticoccidial substances in the period after 3 weeks post-vaccination should be made taking into account the potential negative impact on the duration of immunity of this product.

Overdose (symptoms, emergency procedures, antidotes)
After the administration of a severe overdose (10-fold), mild, transient, clinical signs of coccidiosis were commonly observed without any consequences on the final performance.

Do not mix with any other veterinary medicinal product, except the solvent supplied for use with the veterinary medicinal product.

SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY:
Medicines should not be disposed of via wastewater or household waste.
Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required. These measures should help to protect the environment.

EVANT:

Type I colourless glass vials containing 7 ml, 35 ml or 70 ml of suspension (1,000,

5,000 and 10,000 doses) closed with type I polymeric elastomer closures and

aluminium caps.

HIPRAMUNE T and HIPRACELL (solvents):

Polypropylene vials containing 50 ml, 250 ml or 500 ml of solvent closed with type I

polymeric elastomer closures and aluminium caps.

Pack sizes:

Cardboard box with one vial of EVANT containing 7 ml (1,000 doses) and one vial of

HIPRAMUNE T containing 50 ml.

Cardboard box with one vial of EVANT containing 35 ml (5,000 doses) and one vial

of HIPRAMUNE T containing 250 ml.

Cardboard box with one vial of EVANT containing 70 ml (10,000 doses) and one vial

of HIPRAMUNE T containing 500 ml.

Cardboard box with one vial of EVANT containing 7 ml (1,000 doses) and one vial of

HIPRACELL containing 50 ml.

Cardboard box with one vial of EVANT containing 35 ml (5,000 doses) and one vial

of HIPRACELL containing 250 ml.

Cardboard box with one vial of EVANT containing 70 ml (10,000 doses) and one vial

of HIPRACELL containing 500 ml.

Not all pack sizes may be marketed.

Marketing authorisation holder and manufacturer responsible for batch release:
Laboratorios Hipra, S.A.
Avda. la Selva 135
17170 Amer (Girona), SPAIN

Nil.

UK (NI): EU/2/18/233/001-003

UK (GB): Vm 17533/5004